×
About 7,205 results

Lung Cancer Screening (PDQ®)–Health Professional Version - NIH
https://www.cancer.gov/types/lung/hp/lung-screening-pdq
NIH

Lung Cancer Screening (PDQ®)–Health Professional Version

Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version (NIH)
https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
NIH

NSCLC is any type of epithelial lung cancer other than small cell lung cancer (SCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histologic variants.

Cervical Cancer Screening (PDQ®)–Health Professional Version
https://www.cancer.gov/types/cervical/hp/cervical-screening-pdq

Oct 5th, 2019 - Based on solid evidence, regular screening of appropriate women for cervical cancer with the Pap test reduces mortality from cervical cancer. The benefits of screening women younger than 21 years are small because of the low prevalence of lesions that will progress to invasive cancer. Screening is not beneficial in women older than 65 years if they have had a recent history of negative test res...

Lung Cancer Prevention (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lung/hp/lung-prevention-pdq?cid=eb_govdel
NIH - National Cancer Institute;

Mar 12th, 2020 - Lung cancer risk is largely a function of older age combined with extensive cigarette smoking history. Lung cancer is more common in men than women and in those of lower socioeconomic status. Patterns of lung cancer according to demographic characteristics tend to be strongly correlated with historical patterns of cigarette smoking prevalence. An exception to this is the very high rate of lung ...

Non-Small Cell Lung Cancer Treatment (PDQ®) Health Professional Version
https://www.ncbi.nlm.nih.gov/books/NBK65865/
NIH PDQ Cancer Information Summaries; PDQ Adult Treatment Editorial Board.

Jun 13th, 2019 - This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of non-small cell lung cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. NSCLC

Liver (Hepatocellular) Cancer Screening (PDQ®)–Health Professional Version
https://www.cancer.gov/types/liver/hp/liver-screening-pdq?cid=eb_govdel
National Cancer Institute

In 2020, liver cancer was the sixth most common cancer and third leading cause of cancer death in the world.[1] In the United States, it is estimated that there will be 42,230 new cases diagnosed in 2021 and 30,230 deaths due to this disease.[2] There is a distinct male preponderance among all ethnic groups in the United States.[3]

Liver (Hepatocellular) Cancer Prevention (PDQ®) - National Library of Medicine - PubMed Health
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032568/

May 23rd, 2005 - This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about liver (hepatocellular) cancer prevention. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summar...

Testicular Cancer Screening (PDQ®)–Health Professional Version
https://www.cancer.gov/types/testicular/hp/testicular-screening-pdq?cid=eb_govdel
National Cancer Institute

It is estimated that 9,470 new cases of testicular cancer will be diagnosed in men, and 440 men will die of this disease in the United States in 2021.[1] Testicular cancer is the most common malignancy in men aged 15 to 34 years.[2,3]

Esophageal Cancer Screening (PDQ®)–Health Professional Version
https://www.cancer.gov/types/esophageal/hp/esophageal-screening-pdq?cid=eb_govdel
National Cancer Institute

In 2021, it is estimated that 19,260 Americans will be diagnosed with esophageal cancer, and 15,530 will die of this malignancy. Of the new cases, it is estimated that 15,310 will occur in men and 3,950 will occur in women.[1]

Breast Cancer Screening (PDQ®)–Health Professional Version
https://www.cancer.gov/types/breast/hp/breast-screening-pdq?cid=eb_govdel
National Cancer Institute

Mammography is the most widely used screening modality for the detection of breast cancer. There is evidence that it decreases breast cancer mortality in women aged 50 to 69 years and that it is associated with harms, including the detection of clinically insignificant cancers that pose no threat to life (overdiagnosis). The benefit of mammography for women aged 40 to 49 years is uncertain.[1,2...

Stomach (Gastric) Cancer Screening (PDQ®)–Health Professional Version
https://www.cancer.gov/types/stomach/hp/stomach-screening-pdq?cid=eb_govdel
National Cancer Institute

Barium-meal gastric photofluorography and serum pepsinogen Based on fair evidence, screening with barium-meal photofluorography or serum pepsinogen would not result in a decrease in mortality from gastric cancer in areas with relatively low incidence of the disease, such as the United States.[1-4]

Cancer Screening Overview (PDQ®)–Health Professional Version
https://www.cancer.gov/about-cancer/screening/hp-screening-overview-pdq?cid=eb_govdel

The purpose of this summary is to present an explicit evidence-based approach used in the development of the screening summaries. In reaching conclusions, evidence on the balance of risks and benefits is weighed. Cost and cost-effectiveness, however, is not taken into account. Assignment of levels of evidence associated with such screening tests is also discussed.

Non-Small Cell Lung Cancer Treatment (PDQ®)–Patient Version
https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
Cancer.gov National Cancer Institute

Oct 16th, 2019 - General Information About Non-Small Cell Lung Cancer NSCLC

Non-Small Cell Lung Cancer Treatment (PDQ®) Patient Version
https://www.ncbi.nlm.nih.gov/books/NBK65917/
NIH PDQ Cancer Information Summaries; PDQ Adult Treatment Editorial Board.

Oct 16th, 2019 - This PDQ cancer information summary has current information about the treatment of non-small cell lung cancer. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. NSCLC

Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq?cid=eb_govdel
NIH - National Cancer Institute;

Mar 10th, 2020 - SCLC accounts for approximately 15% of bronchogenic carcinomas. At the time of diagnosis, approximately 30% of patients with SCLC will have tumors confined to the hemithorax of origin, the mediastinum, or the supraclavicular lymph nodes. These patients are designated as having limited-stage disease (LD). Patients with tumors that have spread beyond the supraclavicular areas are said to have ext...

Non-Small Cell Lung Cancer Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq?cid=eb_govdel
NIH - National Cancer Institute;

Mar 13th, 2020 - NSCLC is any type of epithelial lung cancer other than small cell lung cancer (SCLC). The most common types of NSCLC are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma, but there are several other types that occur less frequently, and all types can occur in unusual histologic variants. Although NSCLCs are associated with cigarette smoke, adenocarcinomas may be found in patien...

Bladder Cancer Treatment (PDQ®)–Health Professional Version
https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq?cid=eb_govdel

Bladder cancer is the sixth most common cancer in the United States after lung cancer, prostate cancer, breast cancer, colon cancer, and lymphoma. It is the third most common cancer in men and the eleventh most common cancer in women. Of the roughly 70,000 new cases annually, about 53,000 are in men and about 18,000 are in women. Of the roughly 15,000 annual deaths, more than 10,000 are in men ...

Thyroid Cancer Screening (PDQ®) - National Library of Medicine - PubMed Health
https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0096627/

Aug 29th, 2017 - This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about thyroid cancer screening. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions. This summary is revi...

Breast Cancer Treatment (Adult) (PDQ®)–Health Professional Version
https://www.cancer.gov/types/breast/hp/breast-treatment-pdq

Oct 4th, 2019 - Breast cancer is the most common noncutaneous cancer in U.S. women, with an estimated 62,930 cases of in situ disease and 268,600 cases of invasive disease in 2019.[1] Thus, fewer than one of six women diagnosed with breast cancer die of the disease. By comparison, it is estimated that about 66,020 American women will die of lung cancer in 2019. Men account fo...

ACR Appropriateness Criteria® Lung Cancer Screening.
https://doi.org/10.1016/j.jacr.2018.09.025
Journal of the American College of Radiology : JACR; , Donnelly EF et. al.

Nov 6th, 2018 - Lung cancer remains the leading cause of cancer death in both men and women. Smoking is the single greatest risk factor for the development of lung cancer. For patients between the age of 55 and 80 with 30 or more pack years smoking history who currently smoke or who have quit within the last 15 years should undergo lung cancer screening with low-dose CT. In patients who do not meet these crite...